Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | XPO1 | O14980 | 1/20 | 0.32 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.31 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.31 |
| ▸ | CDK9 | P50750 | 1/20 | 0.31 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.31 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.31 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5043944 | 0.79 | PSMB8 (0.38) | MEN1POLBMAPK1KMT2APSMB8 | |
| SCHEMBL5043964 | 0.72 | — | — | |
| SCHEMBL16763557 | 0.72 | APP (0.50) | MEN1POLBMAPK1KMT2APSMB8 | |
| SCHEMBL13476598 | 0.69 | MEN1 (0.32) | MEN1POLBMAPK1KMT2A | |
| SCHEMBL1245204 | 0.69 | HPGD (0.42) | MEN1MAPK1KMT2ADYRK1A | |
| SCHEMBL5039467 | 0.68 | — | — | |
| SCHEMBL16515901 | 0.68 | — | — | |
| SCHEMBL5041714 | 0.68 | — | — | |
| SCHEMBL4371362 | 0.68 | — | — | |
| SCHEMBL24656024 | 0.68 | ERCC5 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1715840-B1 | KERATIN DYEING COMPOSITIONS CONTAINING BICYCLIC FUSED 5-5 HETEROAROMATIC DYES | PROCTER & GAMBLE (US) | 2008-12-03 | — | — | EP | claimed |
| EP-1715840-B1 | KERATIN DYEING COMPOSITIONS CONTAINING BICYCLIC FUSED 5-5 HETEROAROMATIC DYES | PROCTER & GAMBLE (US) | 2008-12-03 | — | — | EP | disclosed |
| US-7303590-B2 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | THE PROCTER & GAMBLE COMPANY (US) | 2007-12-04 | — | — | US | disclosed |
| EP-1715840-A1 | KERATIN DYEING COMPOUNDS, KERATIN DYEING COMPOSITIONS CONTAINING THEM, AND USE THEREOF | The Procter and Gamble Company (US) | 2006-11-02 | — | — | EP | disclosed |
| US-20050193502-A1 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | PROCTER, GAMBLE COMPANY, THE | 2005-09-08 | — | — | US | disclosed |
| WO-2005077324-A1 | KERATIN DYEING COMPOUNDS, KERATIN DYEING COMPOSITIONS CONTAINING THEM, AND USE THEREOF | THE PROCTER & GAMBLE COMPANY (US) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050193502-A1 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | KRT18, KLK5, CKMT1A; CKMT1B | MEN1 4806/4885POLB 1157/4885MAPK1 2619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.